Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
about
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Future prospects of therapeutic clinical trials in acute myeloid leukemia.Optimization based tumor classification from microarray gene expression data.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Gemtuzumab ozogamicin: time to resurrect?Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.Acute promyelocytic leukemia: a case-based review.Acute promyelocytic leukaemia:a review.Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate.Antibody-based treatment of acute myeloid leukaemia.Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyTherapeutic research in untreated acute promyelocytic leukemia.Monoclonal antibody therapy of leukaemias and lymphomas.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinEffective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinTargeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.Novel targeted drug therapies for the treatment of childhood acute leukemiaGemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.What happened to anti-CD33 therapy for acute myeloid leukemia?Current treatment strategy of acute promyelocytic leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Novel approaches to pediatric leukemia treatment.Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.Treatment of relapsed acute promyelocytic leukemia with gemtuzumab ozogamicin and all-trans retinoic acid.Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel.Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.The Role of Monoclonal Antibodies in the Management of Leukemia.Applications of monoclonal antibodies for the treatment of hematological malignancies
P2860
Q27851694-78A9964C-2D01-4C18-B830-416684699C6CQ30244168-8AC8F251-D34B-4EAD-BB60-EA299DFB10E6Q33822080-54121107-655C-4AE4-B03D-DFA9E9684E48Q33903030-372E85DF-9A8D-4AB9-A5BC-80E90058B4E4Q34300325-8649A927-FEB8-4A16-8804-EECCBEEDCED7Q34764504-329DF812-3070-4C0F-AE98-6C98B0A18041Q34870833-4D71024C-11C2-4201-90AC-5F9A8DE53321Q35127005-3C019942-4D64-444B-9ACE-D66E59E22B99Q35183767-03BE9654-6239-47EA-9A81-B04BEBD50024Q35186873-7CCFA8EF-8B98-4C66-A147-7FA08DD0E6F8Q35609792-DE5FF063-59FB-4DE4-95EA-78F539266824Q35873771-F3A79098-E10D-4448-89DB-1E164D8445FDQ35980938-88CF7794-91DF-4291-8F31-8BA13A6EBBDCQ36058588-CEED1E9F-867D-4074-9BC3-EA76B09C7E24Q36103497-1ECDFB88-F6DC-402C-B28F-391BE71A69C6Q36239669-C84BB455-D5D3-4053-A2D0-F65164421C12Q36367816-2DB38823-3A7F-4DBD-8A81-A9760FFD2568Q36430103-AB0278E4-0ECC-4FBB-880E-F960C129AAA0Q36654598-C455AE71-78B5-42FA-9B8C-AC3E0D86BFB6Q36832124-5E1EE860-F8D5-440B-9563-2C0B0714A976Q36932014-06662226-BFCA-405C-87A8-ABB8BA0F7AC4Q36938551-B43FE2D9-D0B4-436C-8EB7-7A82F3E54864Q37199950-ABE97673-823E-4D4C-9B58-4E1B180A36DFQ37477482-EFADEE3A-CD4D-447D-8A4C-E162439D6F20Q37818248-370C71C0-B843-43DF-8240-1278C0E94265Q37959880-C3C9DEA7-AA12-444C-8C45-6BCE8A547C16Q37971327-08A80BB4-96E8-463C-8E4E-96E76830B7EDQ38109541-D1D8A4F6-DB6D-4B2B-A700-5EC3F100D2E2Q38500371-82E17365-BD55-400D-920B-85F598E460D0Q39506455-9FB2217F-D234-4C3D-B73F-86D85624D55BQ40413191-25552189-9DDE-4C6E-8689-36F393810909Q40552183-0F04F204-EFA5-4D5A-925B-F11771CFAB30Q43195338-6E567588-113F-4F8A-8D54-8569CB8E1E8AQ44452171-B16CD3BC-30F8-43ED-B808-E45288D7AC9DQ48791883-D17079B3-6A2A-4505-B0DF-53203749BB0BQ54592312-9F86FD45-9699-4DA5-9FAB-1781B512E90CQ55506612-76825900-959F-41D5-8219-214588C39322Q57904664-8520B3D6-9467-4B37-B03C-A239FAE3DF8D
P2860
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Experience with gemtuzumab ozo ...... acute promyelocytic leukemia.
@en
Experience with gemtuzumab ozogamycin
@nl
type
label
Experience with gemtuzumab ozo ...... acute promyelocytic leukemia.
@en
Experience with gemtuzumab ozogamycin
@nl
prefLabel
Experience with gemtuzumab ozo ...... acute promyelocytic leukemia.
@en
Experience with gemtuzumab ozogamycin
@nl
P2093
P50
P1433
P1476
Experience with gemtuzumab ozo ...... acute promyelocytic leukemia.
@en
P2093
Elihu H Estey
Francis J Giles
Miloslav Beran
Sherry A Pierce
Stefan H Faderl
P304
P356
10.1182/BLOOD-2001-12-0174
P407
P577
2002-06-01T00:00:00Z